依达拉奉右莰醇与丁苯酞氯化钠注射液联合治疗脑梗死的临床疗效及对神经功能、日常生活能力的影响研究  

Study on clinical efficacy of edaravone and dexborneol combined with butylphthalide sodium chloride injection in the treatment of cerebral infarction and its influence on neurological function and daily living ability

作　　者：朱乃刚 ZHU Nai-gang(Neurology Department,Feicheng People's Hospital,Feicheng 271600,China)

机构地区：[1]肥城市人民医院神经内科,271600

出　　处：《中国实用医药》2024年第22期1-5,共5页China Practical Medicine

摘　　要：目的 探讨依达拉奉右莰醇与丁苯酞氯化钠注射液联合治疗脑梗死的临床疗效及对神经功能、日常生活能力的影响。方法 92例脑梗死患者,随机分为对照组和研究组,每组46例。对照组采用丁苯酞氯化钠注射液进行治疗,研究组在对照组的基础上联合使用依达拉奉右莰醇进行治疗。对比两组患者治疗前后炎性因子[白细胞介素-8(IL-8)、C反应蛋白(CRP)、白细胞介素-10(IL-10)]水平、血清神经因子[脑源性神经营养因子(BDNF)、神经元特异性烯醇化酶(NSE)、神经生长因子(NGF)]水平、神经功能缺损程度、日常生活能力以及治疗效果。结果 治疗后,相较于对照组的(21.32±3.67)ng/ml、(10.22±1.37)ng/L、(10.54±2.18)mg/L,研究组的IL-8(13.49±3.58)ng/ml、IL-10(8.48±1.09)ng/L、CRP(6.41±2.13)mg/L更低,差异具有统计学显著性(P<0.05)。治疗后,相较于对照组的(126.40±11.31)pg/ml、(4.36±1.12)ng/ml、(36.12±2.16)μg/L,研究组的NGF(151.48±13.47)pg/ml、BDNF(5.69±1.04)ng/ml更高,NSE(22.86±2.67)μg/L更低,差异具有统计学显著性(P<0.05)。治疗后,研究组的美国国立卫生研究院卒中量表(NIHSS)评分(5.41±2.18)分低于对照组的(10.65±3.22)分,日常生活能力量表(ADL)评分(64.49±3.68)分高于对照组的(53.48±3.45)分,差异具有统计学显著性(P<0.05)。研究组治疗总有效率93.48%明显高于对照组的78.26%,差异具有统计学显著性(P<0.05)。结论 依达拉奉右莰醇与丁苯酞氯化钠注射液联合治疗治疗脑梗死患者有其独特优势,在炎症水平、神经功能和日常生活能力等多个方面均表现出积极的治疗效果。Objective To explore the clinical efficacy of edaravone and dexborneol combined with butylphthalide sodium chloride injection in the treatment of cerebral infarction and its influence on neurological function and daily living ability.Methods 92 patients with cerebral infarction were randomly divided into the control group and the study group,with 46 cases in each group.The control group was treated with butylphthalide sodium chloride injection,while the study group was treated with edaravone and dexborneol in combination with the treatment in the control group.Patients in both groups were compared in terms of levels of inflammatory factors [interleukin-8(IL-8),C-reactive protein(CRP),interleukin-10(IL-10)],serum neurofactors [brainderived neurotrophic factor(BDNF),neuron-specific enolase(NSE),nerve growth factor(NGF)],as well as the degree of neurological deficits,daily living ability,and therapeutic effect.Results After treatment,compared with(21.32±3.67) ng/ml,(10.22±1.37) ng/L,(10.54±2.18) mg/L in the control group,IL-8 of(13.49±3.58) ng/ml,IL-10 of(8.48±1.09) ng/L,and CRP of(6.41±2.13) mg/L in the study group were lower,and the difference was statistically significant(P<0.05).After treatment,compared with(126.40±11.31) pg/ml,(4.36±1.12) ng/ml,and(36.12±2.16) μg/L in the control group,the study group had a higher NGF of(151.48±13.47) pg/ml and BDNF of(5.69±1.04) ng/ml,and a lower NSE of(22.86±2.67) μg/L,and the difference was statistically significant(P<0.05).After treatment,the study group had a lower National Institutes of Health Stroke Scale(NIHSS) score of(5.41±2.18) points than(10.65±3.22) points in the control group,and a higher activities of daily living(ADL) score of(64.49±3.68) points than(53.48±3.45) points in the control group;the difference was statistically significant(P<0.05).The total effective rate of treatment in the study group was 93.48%,which was significantly higher than 78.26% in the control group,and the difference was statistically significant(P<0.05).Conclusion Edarav

关 键 词：依达拉奉右莰醇 丁苯酞氯化钠注射液 脑梗死 临床疗效 神经功能 日常生活能力 

分 类 号：R743.33[医药卫生—神经病学与精神病学]